Illumina (ILMN) Expected to Announce Quarterly Earnings on Thursday

Illumina (NASDAQ:ILMN) is expected to be issuing its Q4 2025 results after the market closes on Thursday, February 5th. Analysts expect the company to announce earnings of $1.22 per share and revenue of $1.0997 billion for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 5, 2026 at 4:30 PM ET.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The firm’s revenue was up .4% on a year-over-year basis. During the same quarter last year, the firm posted $1.14 earnings per share. On average, analysts expect Illumina to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Illumina Stock Down 1.5%

Shares of Illumina stock opened at $149.86 on Thursday. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. Illumina has a 12-month low of $68.70 and a 12-month high of $155.53. The company has a market cap of $22.90 billion, a P/E ratio of 33.60, a PEG ratio of 2.52 and a beta of 1.41. The company’s fifty day simple moving average is $137.06 and its two-hundred day simple moving average is $114.34.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ILMN shares. Zacks Research cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 31st. Guggenheim lifted their price objective on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research report on Monday. Weiss Ratings reissued a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Canaccord Genuity Group raised their target price on Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a research note on Monday. Finally, UBS Group upped their price target on Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Six equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Illumina presently has an average rating of “Hold” and an average price target of $127.18.

Insider Activity at Illumina

In other Illumina news, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the transaction, the insider owned 17,887 shares in the company, valued at approximately $2,434,241.83. The trade was a 1.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Scott Gottlieb bought 500 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was bought at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the acquisition, the director directly owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. This represents a 4.16% increase in their position. The SEC filing for this purchase provides additional information. 0.17% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Illumina

Several large investors have recently modified their holdings of the stock. Quarry LP purchased a new stake in Illumina during the 3rd quarter valued at about $32,000. Advisory Services Network LLC bought a new position in shares of Illumina in the third quarter worth approximately $102,000. Headlands Technologies LLC purchased a new stake in shares of Illumina during the second quarter valued at approximately $165,000. Glenmede Investment Management LP bought a new stake in shares of Illumina during the third quarter valued at approximately $220,000. Finally, Voleon Capital Management LP purchased a new position in Illumina in the 3rd quarter worth approximately $220,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.